Borea Therapeutics
Borea Therapeutics is an innovative biotech start-up based in Milan, Italy, focused on developing next-generation viral vectors for targeted gene therapy. Their mission is to create safe and effective therapies for patients with genetic or chronic diseases by leveraging proprietary platforms that modify adeno-associated viral vectors (AAV) for increased selectivity and reduced dosage. The company was founded by Professor Paul Heppenstall and EMBLEM, with backing from Sofinnova Partners, and builds upon scientific discoveries from EMBL.
Industries
Nr. of Employees
small (1-50)
Borea Therapeutics
Via Visconti di Modrone, 18, 20122 Milan, Italy
Patents
Products
Modified AAV gene therapy platform
A platform of chemically modified AAV vectors engineered to alter tropism for selective in vivo targeting and to reduce required vector dose.
Modified AAV gene therapy platform
A platform of chemically modified AAV vectors engineered to alter tropism for selective in vivo targeting and to reduce required vector dose.
Services
Collaborative partnerships and technology transfer arrangements to translate academic discoveries into applied gene therapy tools.
Collaborative partnerships and technology transfer arrangements to translate academic discoveries into applied gene therapy tools.
Expertise Areas
- Gene vector engineering
- Targeted in vivo gene delivery
- Platform development for gene therapy
- Translational research and technology transfer
Key Technologies
- Adeno-associated virus (AAV) vectors
- Chemical modification of viral capsids
- Vector tropism engineering
- In vivo targeted gene delivery
News & Updates
On June 30, 2021, Borea Therapeutics received seed funding from Sofinnova Partners.
On June 30, 2021, Borea Therapeutics announced it received seed funding from Sofinnova Partners.
On June 30, 2021, Borea Therapeutics received seed funding from Sofinnova Partners.
On June 30, 2021, Borea Therapeutics announced it received seed funding from Sofinnova Partners.